Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study*

Blanco, Francisco J.; Silva-Díaz, Maite; Vila, V.; Seoane‐Mato, Daniel; Pérez-Ruiz, Fernando; Juan-Mas, Antonio; Pego‐Reigosa, José María; Narváez, Javier; Quilis, Neus; Cortés, Raúl; Pérez, Antonio Romero; Canales, Dolores Fábregas; Gayá, Teresa Font; Ferrer, Carolina Bordoy; Sánchez-Piedra, Carlos; Dı́az-González, Federico; Bustabad-Reyes, Sagrario

doi:10.1016/j.reumae.2020.01.005

Cited by 29 publications

(31 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Los datos fueron recogidos con una amplia distribución nacional y procedentes de centros públicos y privados. El perfil de los pacientes es similar a los del último estudio de prevalencia de artrosis sintomática en España 2 , por lo que los resultados se podrían considerar generalizables para la población nacional.…”

Section: Discussionunclassified

“…Consiste en un proceso degenerativo que afecta al cartílago articular y al hueso subcondral, y que se acompaña de dolor, rigidez, discapacidad y cambios radiográficos. Su localización más habitual es la columna vertebral, especialmente en la zona lumbar, rodillas, caderas o manos 2 , 3 . La prevalencia de la artrosis aumenta con la edad y afecta más a las mujeres que a los varones 4 .…”

Section: Introductionunclassified

“…La prevalencia de la artrosis aumenta con la edad y afecta más a las mujeres que a los varones 4 . En España, un reciente estudio sitúa su prevalencia sintomática en un 29,35%, con su valor más alto en las mujeres de más de 80 años seguido de las mujeres entre 70 y 79 años 2 .…”

Section: Introductionunclassified

See 2 more Smart Citations

Validación de la escala de convivencia con artrosis en la población española

et al. 2021

View full text Add to dashboard Cite

Objetivo Presentar los resultados psicométricos de la escala de convivencia con artrosis (EC-Artrosis) en la población española. Diseño Estudio observacional, multicéntrico y transversal, con retest en una fracción de la muestra. Emplazamiento Centros públicos y privados de atención primaria y secundaria, así como asociaciones de pacientes con artrosis de Navarra, La Rioja, Madrid, Valencia y Málaga. Participantes La muestra estuvo compuesta por un total de 291 pacientes con diagnóstico de artrosis por su médico, en cualquier estadio de la enfermedad de atención primaria o especializada, nacionalidad española, y no hospitalizados. Intervenciones De manera adicional a la EC-Artrosis, se incluyó un cuestionario sociodemográfico y escalas para evaluar el apoyo social percibido por el paciente (DUFSS), la calidad de vida relacionada con la salud (WHOQOL-BREF) y la escala de satisfacción con la vida del paciente. Mediciones principales Se analizaron las propiedades psicométricas de la escala EC-Artrosis, tales como viabilidad y aceptabilidad, fiabilidad (consistencia interna y estabilidad), precisión y validez de constructo (convergente, interna y para grupos conocidos). Resultados El 100% de los datos fueron computados. La calidad de los datos y la aceptabilidad fueron excelentes. El alfa de Cronbach para el total de la escala fue de 0,87 y el índice de homogeneidad de 0,22. El ICC para el total de la escala fue de 0,88. En cuanto a la precisión, el valor del EEM fue de 5,18 (<½DE = 7,47). Conclusiones La EC-Artrosis ha mostrado ser un instrumento válido y fiable para evaluar la convivencia del paciente con artrosis a nivel nacional.

show abstract

Section: Discussionunclassified

Section: Introductionunclassified

See 1 more Smart Citation

Validación de la escala de convivencia con artrosis en la población española

et al. 2021

View full text Add to dashboard Cite

show abstract

“…According to the EPISER study [4] (2016), the prevalence of OA (one or more locations) in subjects 40 years or older in Spain was 29.4%, and figures for different locations were as follows: lumbar spine (15.5%), cervical spine (10.1%), hips (5.1%), knees (13.8%) and hands (7.7%). Data from the 2017 National Health and Wellness Survey in Spain [5] showed that the prevalence of OA diagnosed by a physician in the last 12 months was 17.5% and at any time 22.6% in the total sample and 29.8% in subjects aged 40 or over.…”

Section: Introductionmentioning

confidence: 99%

Unmet Needs in the Osteoarthritis Chronic Moderate to Severe Pain Management in Spain: A Real Word Data Study

Castro-Domínguez

Negrín²,

Pérez

et al. 2021

Rheumatol Ther

View full text Add to dashboard Cite

show abstract

“…[10][11][12] Nowadays, OA prevalence is the highest among all rheumatological diseases. 13,14 In Spain, OA affects up to 29.4% of people aged 40 or older, 15 with pain as a core symptom in many patients: up to 56.5% of OA patients suffered from moderate to severe pain according to the 2017 Spanish National Health Survey (SNHS). 16 This health condition can have a tremendous individual and socioeconomic burden.…”

Section: Introductionmentioning

confidence: 99%

Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain

Rejas‐Gutiérrez

Sicras‐Mainar²,

Darbà

2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Background: Opioids are widely used in moderate-to-severe chronic pain which is non-responsive to standard analgesics. Prescriptions have increased in Europe in the last decade, although remain lower than in USA. This work projected the future utilization and costs of opioids in chronic osteoarthritis (OA) pain in the Spanish National Health System (NHS). Methods: An epidemiological model was populated with the opioid dispensing trends from 2010 to 2019 using Spanish Medicinal Agency rates of opioid utilization in subjects over 18 years of age and the real-world OPIOIDS study to estimate chronic-OA-pain patients receiving opioids. A best-fitted trend analysis model was applied estimating the likely number of DHD (defined daily dose/1000 inhabitants per day) to calculate projected opioid utilization and costs for the period 2020–2029. Results: In 2010, an estimated 5.67 DHD were dispensed for the equivalent of 217,076 chronic OA pain patients per day [1.99 DHD, 76,084 refractory to non-steroidal anti-inflammatory drugs (NSAIDs)]. From these trends and OA prevalence, the projected number of DHDs is expected to increase more than threefold to 17.98 DHDs by the year 2029 for the equivalent of 727,356 chronic OA pain patients per day (8.18 DHD, 330,720 refractory to NSAIDs); 41.8% on strong opioids. The estimated cost was €116.9m (€45.0m in NSAID-refractory OA) in 2010 rising by 222% to €376.1m (€199.7m refractory to NSAIDs) by 2029. Conclusion: Chronic-OA-pain-related opioid dispensing and costs to the NHS are set to increase more than threefold from 2010 to 2029 in Spain. Using opioids for OA pain is concerning given disease chronicity and other related costs not computed in these projections. Plain language summary • Opioids are widely used in chronic pain which is non-responsive to standard analgesics. Prescriptions have increased in Europe, although remain lower than in USA. Osteoarthritis (OA) is a degenerative joint disease usually accompanied by pain. Despite not recommended, opioids use in OA have been expanded because this health condition is increasing with ageing and, also, because physicians both primary and specialist boosted their use. • This study aimed to quantify the current burden of opioids used for chronic moderate-to-severe OA pain by estimating the number of defined daily doses per 1000 inhabitants per day (DHD) and associated costs, and to forecast the likely burden on the National Health System (NHS) in Spain for the years 2020–2029. • In 2010, an estimated 5.67 DHDs were dispensed for the equivalent of 217,076 chronic OA pain patients per day. From these trends, the projected number of DHDs is expected to increase more than threefold to 17.98 DHDs by the year 2029 for the equivalent of 727,356 chronic OA pain patients per day; 41.8% on strong opioids. The estimated cost was €116.9m in 2010 rising by 222% to €376.1m by 2029. • Chronic OA-pain-related opioid dispensing and costs to the NHS are set to increase substantially (threefold to more than fourfold) from 2010 to 2029 in Spain. Thus, using opioids for OA pain is concerning given disease chronicity, aging population and other related costs not computed in these projections. Our findings can inform payors and clinicians about ongoing discussions on appropriate analgesic management for longer-term OA pain, including resource requirements at a national level. Clinicians who prescribe opioids for OA pain should consider the potential implications of side effects such as sedation, cognitive deterioration, incremental need of caregivers, particularly in older people, and carefully consider the risk–benefit balance.

show abstract

Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study*

Cited by 29 publications

References 18 publications

Validación de la escala de convivencia con artrosis en la población española

Validación de la escala de convivencia con artrosis en la población española

Unmet Needs in the Osteoarthritis Chronic Moderate to Severe Pain Management in Spain: A Real Word Data Study

Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain

Contact Info

Product

Resources

About